Miglustat: all 22 studies that test it
Page 1 of 1. Open to participants first (1), then studies with results posted, then the rest; newest registration first within each.
- A Study to Evaluate the Safety, Efficacy, PK, PD and Immunogenicity of Cipaglucosidase Alfa/Miglustat in IOPD Subjects Aged 0 to <18RecruitingNCT04808505Phase 3
- A Study Comparing ATB200/AT2221 With Alglucosidase Alfa/Placebo in Adult Subjects With Late-onset Pompe DiseaseCompletedNCT03729362Phase 3Results posted
- Synergistic Enteral Regimen for Treatment of the GangliosidosesTerminatedNCT02030015Phase 4Results posted
- Clinical Study to Evaluate the Long Term Efficacy, Safety and Tolerability of Miglustat in Patients With Stable Type 1 Gaucher DiseaseCompletedNCT00319046Phase 3Results posted
- Testing Miglustat Administration in Subjects With Spastic Paraplegia 11CompletedNCT04768166Phase 2
- ZIP Study-OL Study of Safety, PK, Efficacy, PD, Immunogenicity of ATB200/AT2221 in Pediatrics Aged 0 to < 18 y.o. w/LOPDActive, not recruitingNCT03911505Phase 3
- Safety and Efficacy of Miglustat in Chinese NPC PatientsCompletedNCT03910621Phase 4
- Effects of Miglustat Therapy on Infantile Type of Sandhoff and Taysachs Diseases (EMTISTD)TerminatedNCT03822013Phase 3
- Miglustat on Gaucher Disease Type IIIBStatus unknownNCT02520934Not applicable
- A Pilot Study of Zavesca® in Patients With Pompe Disease and Infusion Associated ReactionTerminatedNCT02185651Phase 1
- Application of Miglustat in Patients With Niemann-Pick Type CCompletedNCT01760564Phase 3
- Does a Nasal Instillation of Miglustat Normalize the Nasal Potential Difference in Cystic Fibrosis Patients ?CompletedNCT00945347Phase 2
- Miglustat in Cystic FibrosisCompletedNCT00742092Phase 2
- Pharmacokinetics, Safety and Tolerability of Zavesca (Miglustat) in Patients With Infantile Onset Gangliosidosis: Single and Steady State Oral DosesCompletedNCT00672022Phase 3
- Miglustat / OGT 918 in the Treatment of Cystic FibrosisTerminatedNCT00537602Phase 2
- Miglustat in Niemann-Pick Type C DiseaseCompletedNCT00517153Phase 2
- Pharmacokinetics and Tolerability of Zavesca® (Miglustat) In Patients With Juvenile GM2 GangliosidosisCompletedNCT00418847Phase 2
- Saccadic Eye Movements in Patients With Niemann-Pick Type C DiseaseCompletedNCT00316498Phase 1
- Glycosphingolipid Inhibition and Spermatogenesis in Man: A Pilot Study (MIG 2)CompletedNCT00194649Phase 4
- OGT 918-006: A Phase I/II Randomized, Controlled Study of OGT 918 in Patients With Neuronopathic Gaucher DiseaseCompletedNCT00041535Phase 2
- Phase II Study of the Safety and Surrogate Marker Efficacy of Butyldeoxynojirimycin (SC-48334) and AZT in Symptomatic HIV-1 Infected Patients With 200 - 500 CD4+ Cells/mm3. (NOTE: Asymptomatic HIV-1 Infected Patients Also Eligible)CompletedNCT00002079Phase 2
- Phase I Rising Dose Tolerability Study of SC-48334 in Patients With Acquired Immunodeficiency Syndrome (AIDS) and Advanced AIDS Related ComplexCompletedNCT00000692Phase 1